India’s first corona vaccine Kovaxin gets human testing permission, trials will start next month
New Delhi: Kovaxin (COVAXIN), India’s first potential vaccine for COVID-19, has received human trials for Phase I and II from drug regulator DGCI. This vaccine has been developed by Bharat Biotech. Vaccine trials on humans are planned to begin in July this year.
The vaccine has been developed in collaboration with the Indian Institute of Medical Research (ICMR) and the National Institute of Virology (NIV). The strain of the virus was Isolated at NIV, Pune and sent to Bharat Biotech, where the indigenous vaccine was developed.
Let me tell you that more than 100 vaccines of corona virus are currently in operation worldwide, but still no success in this field. Today, a vaccine was allowed to be used in China today as well. This vaccine has been developed by the Research Unit of the Chinese Army and the Casino Biologics.
This Ad5-nCoV vaccine is among the eight possible Chinese vaccines that have been approved for trials on humans. However, Cancino said that the vaccine will be for military use only because it cannot be used on a large scale without the permission of the Department of Logistics.